Sun Yat-sen University
Clinical trials sponsored by Sun Yat-sen University, explained in plain language.
-
New cocktail of drugs shows promise against rare lymphoma
Disease control Not yet recruitingThis study is testing a combination of three drugs—sintilimab, chidamide, and azacitidine—as a first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and their response will guide further treat…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 19:36 UTC
-
New drug aims to keep lymphoma in check after CAR-T treatment
Disease control Not yet recruitingThis study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 19:34 UTC
-
Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive ritu…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 19:33 UTC
-
New triple therapy aims to shrink pancreatic tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether giving a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and chemotherapy before surgery can help people with high-risk or borderline resectable pancreatic cancer. The study will enroll 30 participants and track ho…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Could less immunotherapy be just as good for advanced nose cancer?
Disease control Not yet recruitingThis phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive eit…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Radiation after surgery may keep adrenal cancer at bay
Disease control Not yet recruitingThis study looks at whether giving radiation therapy after surgery can help prevent high-risk adrenocortical carcinoma from coming back. 58 patients who had their tumor removed will be randomly assigned to either receive radiation or just be watched. The main goal is to see if ra…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New combo attack before surgery aims to beat rare sinonasal cancer
Disease control Not yet recruitingThis phase 2 trial tests a new approach for people with advanced sinonasal cancer, a rare tumor in the nasal cavity and sinuses. Before surgery, patients receive standard chemotherapy (docetaxel and cisplatin) plus two immunotherapy drugs (sintilimab and ipilimumab). The goal is …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Can a Two-Drug antiviral combo boost survival in liver cancer patients?
Disease control Not yet recruitingThis study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Triple threat: immunotherapy, chemo, and radiation take on rectal cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New drug could beat steroids for saving sight in thyroid eye disease
Disease control Not yet recruitingThis study compares two treatments given after emergency eye surgery for people with thyroid eye disease who have vision loss. One group gets teprotumumab, a newer drug that blocks a growth factor, and the other gets high-dose steroids. The goal is to see which one better improve…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
Experimental combo targets stomach cancer fluid after other treatments fail
Disease control Not yet recruitingThis study tests a three-part treatment for people with advanced digestive tract cancers that have caused fluid buildup in the belly (malignant ascites) and haven't responded to standard therapies. The treatment combines low-dose radiation to the abdomen with two injected drugs: …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Triple therapy aims to wipe out rectal tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests a new approach for people with high-risk locally advanced rectal cancer. Participants will receive a short course of radiation with a boost to the tumor, combined with chemotherapy (capecitabine and oxaliplatin) and an immunotherapy drug (tislelizumab). T…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Gut bacteria may tame 'Silent' uric acid threat
Disease control Not yet recruitingThis study tests whether taking a daily probiotic supplement can lower blood uric acid in people who have high levels but no gout symptoms. Researchers will give 68 adults either the probiotic or a placebo for several weeks, measuring changes in uric acid, kidney function, and gu…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New drug cocktail aims to beat back aggressive throat cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New hope for endometrial cancer: targeted drug plus chemo shows promise
Disease control Not yet recruitingThis phase 2 trial tests whether adding the targeted drug fruquintinib to standard chemotherapy (paclitaxel and carboplatin) works better than chemo alone for advanced or recurrent endometrial cancer that is mismatch repair-proficient (pMMR). About 128 participants will be random…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New triple therapy aims to reverse early diabetes
Disease control Not yet recruitingThis study tests whether a combination of three diabetes drugs (tirzepatide, empagliflozin, and pioglitazone) can help people newly diagnosed with type 2 diabetes achieve remission—meaning their blood sugar stays normal even after stopping medication. About 296 adults will take e…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New combo therapy targets tough lung cancer gene
Disease control Not yet recruitingThis study tests a new drug combination (goselasib plus other drugs) as a first treatment for people with advanced or spreading non-small cell lung cancer that has a specific gene change called KRAS G12C. About 69 adults who have not had prior treatment for their advanced cancer …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New combo therapy aims to stop High-Risk throat cancer from returning
Disease control Not yet recruitingThis phase 3 trial tests whether adding anlotinib (a targeted therapy) to standard chemoradiotherapy and immunotherapy can prevent high-risk nasopharyngeal cancer from coming back. About 412 adults aged 18-65 with advanced throat cancer will be randomly assigned to receive either…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New triple therapy offers hope for hard-to-treat nose and throat cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (chidamide, toripalimab, and anlotinib) in 52 adults with recurrent or metastatic nasopharyngeal carcinoma that has failed at least one prior treatment. The goal is to find the safest dose and see how many patients' tumors shrink. Par…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
Chemo-Free hope: new combo before lung surgery shows promise
Disease control Not yet recruitingThis study tests a new approach for people with early-stage lung cancer who cannot or will not take chemotherapy. Before surgery, patients receive a short course of focused radiation (SBRT) combined with immunotherapy (tislelizumab) and an antiangiogenic drug (anlotinib). The goa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
Triple therapy offers hope for hard-to-treat liver cancer
Disease control Not yet recruitingThis study tests a new combination of treatments for people with a specific liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The treatment includes chemotherapy delivered directly to the liver, along with two oral and intravenous drugs. The goal i…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New hope for relapsed blood cancer: Three-Drug combo enters trials
Disease control Not yet recruitingThis study tests a new combination of three drugs (lisaftoclax, chidamide, and rituximab) in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe and effective dose and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New hope for elderly lymphoma patients: drug cocktail targets aggressive cancer
Disease control Not yet recruitingThis study tests a combination of three drugs—polatuzumab vedotin, rituximab, and chidamide—in elderly patients (70+ or frail 60-69) with untreated diffuse large B-cell lymphoma that has two specific markers (MYC and BCL2). The goal is to see if this mix is safe and effective, ai…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
New eye drug faricimab tested for blinding disease
Disease control Not yet recruitingThis study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, me…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New bendable tube could make heart valve surgery safer
Disease control Not yet recruitingThis trial tests a new device called the ArcFlex Sheath, a bendable tube used during TAVR surgery to replace a faulty aortic valve. The goal is to see if it helps doctors position the new valve more easily and safely compared to a standard sheath. About 180 people who need TAVR s…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Nudge, nudge: text alerts and calendars tested to keep AF patients on blood thinners
Disease control Not yet recruitingThis study tests whether a 'nudge' program—including text reminders, a medication calendar, and an action plan—can help people with atrial fibrillation stick to their blood-thinning medication. About 84 participants will either get the nudges or usual care. Researchers will measu…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
Immunotherapy cocktail aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether adding chemotherapy to the immunotherapy drug toripalimab before surgery helps keep head and neck cancer from coming back. About 154 adults with advanced but operable cancer will get either toripalimab alone or with chemo for two cycles, then have surgery…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
New drug combo aims to shrink Hard-to-Treat throat cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two drugs—scipibaimab and tislelizumab—can shrink tumors in people with recurrent or metastatic nasopharyngeal carcinoma that has worsened after first-line treatment. About 37 adults whose cancer has not responded to platinum chemotherap…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
Hope for Hard-to-Treat lymphoma: Anti-Inflammatory drug joins chemo in new trial
Disease control Not yet recruitingThis study tests whether adding the anti-inflammatory drug celecoxib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with a specific, aggressive type of lymphoma called CD5-positive diffuse large B-cell lymphoma. About 60 adults with newly diagno…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New combo aims to shield bone marrow in tough breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow in people with advanced triple-negative breast cancer who have already tried at least two prior chemotherapies. The study will enroll 29 participants and measure how ofte…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs, tunlametinib and cetuximab β, in 55 people with advanced non-small cell lung cancer that has a KRAS mutation and has not responded to prior treatments. The goal is to see if the combo can shrink tumors and control the disease. …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Promising new combo aims to shrink returning throat tumors
Disease control Not yet recruitingThis study tests a new treatment for people whose nasopharyngeal cancer has come back and cannot be surgically removed. Participants will receive two cycles of a targeted drug (becotatug vedotin) plus an immunotherapy, followed by radiation and continued immunotherapy. The goal i…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
Radiation vs. scalpel: landmark trial seeks best treatment for small liver tumors
Disease control Not yet recruitingThis phase 3 trial compares two treatments for small liver cancer (tumors 5 cm or smaller): surgery to remove the tumor or a precise, high-dose radiation therapy called SBRT. About 312 adults with a single liver tumor will be randomly assigned to one of the two treatments. The st…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New drug duo targets hard-to-treat lung cancer in early trial
Disease control Not yet recruitingThis study tests two drugs together for people with advanced non-small cell lung cancer that has HER2 abnormalities. The drugs are SHR-A1811, which targets HER2, and ivonescimab, which boosts the immune system. The goal is to see if the combination can control the cancer longer. …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New dialysis fluid aims to prevent dangerous mineral loss in ICU patients
Disease control Not yet recruitingThis study tests a new pre-mixed fluid that contains phosphate for patients in the ICU who need continuous kidney dialysis (CRRT). Normally, this treatment can wash out important minerals like phosphate, causing muscle weakness and breathing problems. The new fluid aims to keep p…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New drug combo aims to stop advanced nose cancer from coming back
Disease control Not yet recruitingThis phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a targeted therapy (anlotinib) to standard chemotherapy and radiation can help prevent cancer from returning in people with high-risk, advanced nasopharyngeal carcinoma. About 442 adults aged 18-65 …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
New combo therapy aims to slash liver cancer recurrence after surgery
Disease control Not yet recruitingThis study tests whether combining local tumor treatments (TACE or ablation) with immunotherapy drugs (sintilimab and ipilimumab) before surgery can lower the chance of liver cancer coming back. It involves 105 adults with resectable liver cancer at intermediate-to-high risk of r…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
12-Week home workout aims to strengthen seniors with diabetes and muscle loss
Disease control Not yet recruitingThis study tests a 12-week home exercise program combining aerobic and resistance training for older adults (60+) with type 2 diabetes and early muscle weakness. The goal is to see if short, regular workouts can improve physical activity levels and muscle strength. About 73 parti…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
Could Pre-Surgery chemo boost survival in colon cancer?
Disease control Not yet recruitingThis study compares giving chemotherapy before surgery versus standard surgery-first treatment for people with stage II or III colon cancer that has a high CEA level. About 100 adults aged 18-70 will be randomly assigned to one of two groups. The goal is to see if pre-surgery che…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC
-
Promising drug cocktail aims to shrink rare lymphoma before radiation
Disease control Not yet recruitingThis study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation in people newly diagnosed with stage I or II extranodal NK/T-cell lymphoma, a rare cancer of the immune system. The goal is to see how many patients achieve complete remi…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial
Disease control Not yet recruitingThis study tests whether adding chemotherapy to immunotherapy works better than immunotherapy alone for people with advanced nasopharyngeal cancer whose cancer did not fully respond to initial treatment. About 516 adults aged 18-65 with stage II-III disease will receive either th…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
AI helps target stomach cancer with less harm to healthy organs
Disease control Not yet recruitingThis study tests a new way to deliver radiation for gastric MALT lymphoma. Using AI, the treatment adapts each session to better protect nearby organs. About 25 adults with early-stage disease will take part. The goal is to see if this approach is safe and effective.
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
New hope for rare thymic cancer: targeted drug trial launches
Disease control Not yet recruitingThis study tests a new drug, sacituzumab tirumotecan, in 38 people with advanced thymic epithelial tumors that have worsened after at least one prior treatment. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The goal is to see if it can shrink tu…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Chemo-free triplet aims to outsmart incurable lymphoma
Disease control Not yet recruitingThis study tests a chemotherapy-free combination of three drugs (sonrotoclax, zanubrutinib, and rituximab) in 52 adults with previously untreated follicular lymphoma. The goal is to see if this approach can produce deeper and longer-lasting remissions while being easier to tolera…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
How much eye surgery is best for babies with glaucoma?
Disease control Not yet recruitingThis study looks at children with a rare, severe eye disease called primary congenital glaucoma. It compares three different amounts of a surgery called goniotomy (120°, 240°, or 360°) to see which works best and is safest. The goal is to lower eye pressure and protect vision, bu…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Immunotherapy plus chemo may open door to surgery for inoperable lung cancer
Disease control Not yet recruitingThis study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the com…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug cocktail offers hope for Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) in 30 adults with recurrent or metastatic head and neck cancer that has not responded to previous treatments. The goal is to see if this therapy can shrink tumors and improve survival. Partic…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Could a fibrosis drug boost fertility in adenomyosis?
Disease control Not yet recruitingThis study tests whether nintedanib, a drug that reduces scar-like tissue, can improve the chance of a live birth for women with adenomyosis who have frozen embryos. About 328 women will receive either standard hormone therapy plus nintedanib or hormone therapy alone for three mo…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New drug may keep stage III lung cancer in check after chemoradiation
Disease control Not yet recruitingThis study tests a drug called ivonescimab given for one year after standard chemoradiation in people with stage III lung cancer that cannot be removed by surgery. The goal is to see if it can delay cancer growth. About 63 adults aged 18–75 who have not gotten worse after chemora…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New combo therapy offers hope for hard-to-treat nose cancer
Disease control Not yet recruitingThis study tests a new treatment for people whose nose and throat cancer has returned and cannot be removed with surgery. The treatment combines an immunotherapy drug (PD-1 antibody) with two chemotherapy drugs, followed by targeted radiation. The goal is to see if this approach …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New combo therapy targets hard-to-treat lymphomas in early trial
Disease control Not yet recruitingThis study tests a new drug, zeprumetostat, combined with other treatments for people whose T-cell or NK-cell lymphoma has come back or stopped responding to therapy. The goal is to find safe doses and see if the combination shrinks tumors. About 60 adults will take part in this …
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control Not yet recruitingThis study tests two drugs, adebrelimab and SHR2554, together in about 40 adults whose T-cell lymphoma has come back or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have certain types of T-cell lymphom…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for hard-to-treat head and neck cancer: drug combo before surgery shows promise
Disease control Not yet recruitingThis study tests whether giving two drugs (becotatug vedotin and pucotenlimab) before surgery can shrink tumors in people with recurrent head and neck cancer that has stopped responding to standard treatments. About 42 adults with EGFR-positive cancer will receive 3 cycles of the…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug cocktail aims to stop lung cancer in its tracks
Disease control Not yet recruitingThis study tests whether adding two immunotherapy drugs (tislelizumab and surufatinib) to standard chemoradiation can help people with stage III non-small cell lung cancer that cannot be surgically removed. About 160 participants will be randomly assigned to receive either the tw…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New hope for tough colorectal cancer: drug combo challenge begins
Disease control Not yet recruitingThis study tests whether a new combination of drugs (trifluridine/tipiracil plus fruquintinib) works as well as the current standard (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has not responded to at least two prior treatments. About…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 12, 2026 12:11 UTC
-
Could a common gut drug keep colorectal cancer at bay?
Disease control Not yet recruitingThis study tests whether adding lubiprostone, a drug used for constipation, to standard maintenance therapy can delay cancer recurrence in adults with colorectal cancer that has spread to the lining of the abdomen. About 124 participants who have had surgery to remove visible tum…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 12, 2026 12:09 UTC
-
New hope for tough stomach cancer: triple drug attack
Disease control Not yet recruitingThis study tests a combination of three drugs (disitamab vedotin, tunlametinib, and a PD-1 antibody) in people with advanced stomach cancer that has a specific protein (HER2) and has not responded to at least two prior treatments. The goal is to see if the combo can shrink tumors…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
Arm cuff trick shields kidneys during cancer surgery?
Disease control Not yet recruitingThis study tests if temporarily restricting blood flow to an arm (called ischemic preconditioning) before kidney cancer surgery can reduce kidney damage. About 174 adults having partial nephrectomy will be randomly assigned to receive this technique or standard care. The goal is …
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis study tests a combination of two drugs (trastuzumab Rezetecan and ivonescimab) in 30 people with advanced non-small cell lung cancer that has HER2 gene changes. The goal is to see if the combination can shrink tumors or delay cancer growth. Participants must be 18-75, in goo…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC
-
New hope for advanced breast cancer: drug combo aims to halt tumor growth
Disease control Not yet recruitingThis study tests whether adding entinostat to fulvestrant can help control advanced breast cancer in people whose disease has worsened after standard hormone therapy and CDK4/6 inhibitors. About 50 women aged 18-75 with HR+/HER2- cancer will receive the combination. The main goal…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
New chemo combo aims to slow advanced colon cancer
Disease control Not yet recruitingThis study tests a new chemotherapy combination (FOLFOX8) against a standard one (mFOLFOX6) for people with advanced colorectal cancer that cannot be removed by surgery. About 229 adults will receive one of these treatments along with targeted drugs. The goal is to see if the new…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
Could a heart drug boost colon cancer treatment?
Disease control Not yet recruitingThis study tests if adding a common heart medication (propranolol) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a certain type of colon cancer. About 45 adults with stage II or III colon cancer that is mismatch repair proficient (…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Not yet recruitingThis study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New combo therapy aims to shrink rectal tumors before surgery
Disease control Not yet recruitingThis study tests a new treatment plan for people with a certain type of locally advanced rectal cancer (pMMR/MSS). Participants first get a short course of radiation, then a combination of an immunotherapy drug (QL1706) and chemotherapy. The goal is to shrink or eliminate the tum…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
New study tests minimally invasive heart valve repair to cut hospital stays
Disease control Not yet recruitingThis study tests whether a minimally invasive heart valve repair procedure (TEER) plus standard medication can reduce hospital readmissions over two years in people with moderate mitral regurgitation that worsens with exertion. About 300 participants will be randomly assigned to …
Phase: EARLY_PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 08, 2026 13:13 UTC
-
New drug combo aims to fix dangerous low platelets in cancer patients
Disease control Not yet recruitingThis study tests whether a combination of two drugs (hetrombopag and rhTPO) works better than hetrombopag alone to raise dangerously low platelet counts caused by cancer treatments like chemotherapy. About 204 adults with solid tumors and severe low platelets will be randomly ass…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
Triple-threat before surgery: radiation, chemo, and immunotherapy aim to boost survival in advanced oral cancer
Disease control Not yet recruitingThis study tests whether giving a precise form of radiation (SBRT) along with chemotherapy and immunotherapy before surgery can help people with advanced mouth or throat cancer live longer without the cancer coming back. About 184 adults with untreated, advanced oral or HPV-negat…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Engineered immune cells take on Hard-to-Treat KRAS cancers
Disease control Not yet recruitingThis early-phase study tests a personalized cell therapy (TCR-T) in 25 adults with advanced solid tumors caused by KRAS mutations. Participants must have exhausted standard treatments. The goal is to see if the therapy is safe and can shrink tumors. This is not a cure, as ongoing…
Phase: EARLY_PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 03, 2026 13:13 UTC
-
New hope for lymphoma patients: experimental drug combo enters human trials
Disease control Not yet recruitingThis study tests whether adding the experimental drug lisatoclax to standard chemotherapy (R-CHOP or Pola-R-CHP) can safely improve outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 122 adults aged 18-70 will take part. The goal is to see if the comb…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 02, 2026 11:56 UTC
-
New combo aims to shrink colon tumors before surgery
Disease control Not yet recruitingThis study tests whether a stronger chemotherapy combination (Chinese modified FOLFOXIRI) plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemotherapy (mFOLFOX6) before surgery for people with locally advanced colon cancer (stage II high-risk or stage III).…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 01, 2026 18:08 UTC
-
New combo therapy aims to shrink rectal tumors and avoid surgery
Disease control Not yet recruitingThis phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to a strong chemotherapy and radiation regimen works better than standard chemo plus radiation for people with a certain type of advanced rectal cancer. About 382 adults will be randomly assigned to one…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 01, 2026 18:06 UTC
-
Could a single spinal shot ease pain and speed recovery after major abdominal surgery?
Symptom relief Not yet recruitingThis study tests whether a single dose of morphine given into the spinal fluid before open abdominal surgery can improve how well patients recover. It involves 756 adults scheduled for surgery and compares the spinal injection to a placebo. The goal is to see if this approach red…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 22, 2026 12:07 UTC
-
New surgical wrap aims to cut palate injuries in half
Symptom relief Not yet recruitingThis study compares two ways to lift the soft palate during throat surgery to see which causes fewer injuries. About 138 people aged 2 to 70 who need this type of surgery will be randomly assigned to either the standard double-strap method or a new full-wrap method. The goal is t…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 22, 2026 11:58 UTC
-
Spinal morphine may boost recovery after keyhole gynecologic surgery
Symptom relief Not yet recruitingThis study tests whether adding a single spinal injection of morphine to a standard abdominal wall nerve block improves recovery in women undergoing laparoscopic gynecologic surgery. About 252 women will be randomly assigned to receive either the spinal morphine plus the nerve bl…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 22, 2026 11:57 UTC
-
Taurine trial aims to soothe radiation burns in throat cancer patients
Symptom relief Not yet recruitingThis study tests if taking taurine can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. About 130 adults will be randomly assigned to receive taurine or standard care during their radiation treatment. The goal is to see if tau…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 17, 2026 12:09 UTC
-
New trial aims to beat cancer fatigue with common drug
Symptom relief Not yet recruitingThis study tests whether megestrol acetate, a drug often used for appetite loss, can prevent or reduce severe tiredness in 132 women with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan (T-DXd). Participants will receive either megestrol acetate …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 15, 2026 19:03 UTC
-
Social media and body image: hidden links to postpartum depression?
Knowledge-focused Not yet recruitingThis study will survey 385 women who gave birth within the past 4 weeks to 12 months to understand how often postpartum depression occurs and how it relates to body image dissatisfaction, self-objectification, and comparing appearances on social media. Participants answer online …
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 23, 2026 19:34 UTC
-
Carbs under the microscope: can changing what you eat fix your metabolism?
Knowledge-focused Not yet recruitingThis study looks at how different amounts and types of carbohydrates (like high vs. low glycemic index foods) affect blood sugar, fats, and gut bacteria. Researchers will test four different diets in 20 adults with or at risk for metabolic syndrome. The goal is to understand whic…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:56 UTC
-
Why Can't they stop scrolling? new study dives into college Students' Short-Video addiction
Knowledge-focused Not yet recruitingThis study aims to understand how college students experience addiction to short videos like those on TikTok or Instagram Reels. Researchers will interview 30 students who show signs of addiction to uncover what triggers the behavior, how it affects their emotions and self-contro…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
Could a 'Hands-Off' embryo culture boost IVF success?
Knowledge-focused Not yet recruitingThis study compares two ways of growing embryos in the lab during IVF. One method uses a special incubator and a single culture medium that keeps embryos undisturbed. The other uses standard equipment and multiple media changes. About 478 women will take part to see if the new me…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:55 UTC
-
New eye scan method could unlock secrets of blurry vision disease
Knowledge-focused Not yet recruitingThis study will use a special type of eye scan (ultra-widefield OCTA) to measure blood vessel patterns in people with central serous chorioretinopathy (CSC), a condition that causes fluid buildup and blurry vision. Researchers aim to create a more precise way to analyze these ima…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:07 UTC
-
AI model aims to predict lymphoma treatment success
Knowledge-focused Not yet recruitingThis study will develop an artificial intelligence model to predict how well patients with a rare type of lymphoma (NK/T-cell) respond to their first chemotherapy. Researchers will collect medical images and tissue samples from 100 participants to train the AI. The goal is to hel…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:01 UTC
-
Blood test may spot hidden cancer after surgery
Knowledge-focused Not yet recruitingThis study looks at whether new blood tests can find tiny bits of cancer DNA left after surgery in people with stage III colorectal cancer. About 229 patients will give blood samples, which will be analyzed using two different methods. The goal is to see which test better predict…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:57 UTC
-
New 'Flipped Discharge' model aims to ease stoma care at home
Knowledge-focused Not yet recruitingThis study tests a new approach called 'Flipped Discharge' for people with colorectal cancer who have a stoma after surgery. Instead of focusing care in the hospital, it shifts support to the home, with a nurse visit or video follow-up three days after discharge. The goal is to s…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:12 UTC